Kimball Electronics (KE) Q4 2026 earnings review
Top-Line Reversal Powered by Medical CMO Pivot, But Earnings Quality is Poor
Kimball Electronics is engineering a decisive turnaround in its top-line trajectory, breaking out of a multi-quarter contraction with a 5% sequential sales increase in Q4. FY27 guidance targets 7-9% growth, heavily subsidized by the $60M Helvoet acquisition. However, investors must look past the headline EPS of $0.35. Stripping out a massive $15M one-time gain on an asset disposal, the core business actually posted an adjusted net loss of $0.16M (-$0.01 per share). While the balance sheet is undeniably a fortress—with debt hitting a 4-year low—the legacy Automotive and Industrial segments remain a structural drag on organic profitability.
🐂 Bull Case
10 consecutive quarters of positive operating cash flow ($42.4M in Q4) enabled the company to slash debt to $116.6M, the lowest level in over 4 years. Cash conversion days improved to an impressive 82.
The Helvoet acquisition ensures the Medical segment will exceed one-third of total company sales in FY27. This inorganic boost derisks the transition away from cyclical legacy markets.
🐻 Bear Case
Management touted a 'very good finish', but adjusted EPS collapsed to -$0.01. A $15M gain on disposal masked underlying operational weakness.
Automotive (-3%) and Industrial (-5%) remain in contraction, diluting the benefits of Medical expansion and pressuring overall organic growth (guided at a modest 3-5% for FY27).
⚖️ Verdict: ⚪
Neutral. The strategic pivot to a Medical CMO is the right move, and the balance sheet affords them the flexibility to buy growth. However, core operational profitability is weaker than headline numbers suggest, requiring strict monitoring in early FY27.
Key Themes
GAAP Earnings Contradict Core Reality
Management stated they were 'proud of our results... adjusted operating income was better than estimates.' Yet, a closer look at the data contradicts the positive narrative. The company recorded a $15.0M 'Gain on Disposal' in Q4. When backing out this gain (after-tax impact of -$11.4M) and factoring in restructuring and acquisition costs, Adjusted Net Income turned negative at -$0.16M, and Adjusted EPS dropped to -$0.01 from $0.34 a year ago. The core business is currently losing money on the bottom line.
Inorganic Medical Expansion via Helvoet
The acquisition of Helvoet Polymer Technologies is the centerpiece of FY27's growth strategy. It instantly injects ~$60M in high-margin medical revenue into the pipeline, accounting for nearly half of the projected FY27 total sales growth. This accelerates the timeline for Medical to comprise over 33% of total company sales.
Automotive and Industrial Drag Persists
Kimball's legacy businesses remain a heavy anchor. Automotive sales fell 3% YoY to $169.7M, and Industrial dropped 5% YoY to $93.1M. While the company points to medical as the future, these two segments still make up over 70% of the Q4 revenue mix. Their deceleration caps total organic growth upside.
Working Capital Masterclass
The CFO's 'balance sheet first' approach is yielding massive dividends. Cash Conversion Days (CCD) plummeted to 82—the best result in 17 quarters. This operational discipline generated $42.4M in Q4 operating cash, funding both debt paydowns and strategic medical investments without diluting shareholders.
Macroeconomic & EV Headwinds in Automotive
The global macro environment, specifically changing consumer incentives and reduced demand for previously won North American EV programs, continues to plague the Automotive segment. European steering and braking ramps are not enough to offset the broader industry softness, forcing management to heavily discount near-term auto recovery.
Moving Up the Value Chain in Medical Devices
The strategic combination of the new Indianapolis facility and Helvoet shifts Kimball from basic electronics manufacturing to high-value precision assembly. By targeting complex drug delivery devices, auto-injectors, and precision polymer components, Kimball is capturing a more lucrative, 'sticky' slice of the Medical technology ecosystem.
Other KPIs
Decelerating from 5.2% in 25Q4. While the company claims it beat estimates, the core margin profile contracted year-over-year when stripping out the asset disposal gain, highlighting the margin drag from current medical capacity investments.
Accelerating significantly from earlier quarters. This marks the tenth consecutive quarter of positive operating cash generation, proving that Kimball's liquidity machine remains highly robust despite top-line friction.
Guidance
Reversing. After a 4% decline in FY26 to $1,431M, management expects a 7-9% increase. However, stripping out the $60M Helvoet contribution, organic growth is guided at a much milder 3-5%.
Stable. Compares directly to the 4.6% achieved in FY26. This implies that the accretive margins from Medical growth and the Helvoet acquisition are entirely offset by the planned 40-50 bps margin drag from scaling up the new Indianapolis facility.
Stable. In line with the $50-$60 million targeted during FY26. Heavy investment continues to flow toward the medical pivot.
Key Questions
Gain on Disposal Details
What exactly comprised the $15 million gain on disposal in Q4, and should we expect further divestitures of non-core physical or business assets in FY27?
Helvoet Integration and Margins
With Helvoet slated to add $60 million in FY27 sales, what is its standalone margin profile compared to legacy Kimball, and how long until full operational integration is complete?
Core Profitability Bridge
Given that Q4 adjusted EPS was negative when backing out one-time gains, what specific levers will drive the organic business back to bottom-line profitability in Q1 and Q2 before the Helvoet synergies fully take hold?
EV Demand Contraction
What specific assumptions regarding the North American EV market are baked into the 3-5% organic growth guidance, and is there risk of further automotive program cancellations?